logo
logo

Spexis Achieves First Carb-X Milestone For Its Thanatin Derivatives Program And Receives Funding Of Up To Usd 1.9 Million To Initiate Lead Optimization

Spexis Achieves First Carb-X Milestone For Its Thanatin Derivatives Program And Receives Funding Of Up To Usd 1.9 Million To Initiate Lead Optimization

03/03/22, 1:40 AM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/CH.svgallschwil
ALLSCHWIL, SWITZERLAND / March 3, 2022 / Spexis AG (SIX:SPEX) announced today that it has been awarded the second part of its phased funding grant from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), the global partnership led by Boston University dedicated to supporting the development of antibacterial products to diagnose, prevent and treat drug-resistant infections. Spexis has received this award based upon the achievement of technical milestones within the previously announced CARB-X collaboration for this program. The award will support the continuation of the "thanatin derivatives program" belonging to Spexis' novel Outer Membrane Protein Targeting Antibiotic (OMPTA) class of antibiotics to potentially treat life-threatening infections caused by difficult-to-treat Gram-negative bacteria.

Company Info

Company
Spexis
Location
allschwil, basel-landschaft, switzerland
Additional Info
Spexis is a clinical-stage biopharmaceutical company based in Allschwil, Switzerland focused on rare diseases and oncology. The current pipeline of the company is a combination of two legacy companies, Polyphor and EnBiotix, which merged in December 2021. The combined company has been renamed to Spexis AG and is trading on the SIX Swiss Exchange under the symbol SIX:SPEX. For further information please visit: www.spexisbio.com .